X0306 5 2013-12-31 0 0 1 0001425205 Lion Biotechnologies, Inc. GNBP 0001471149 Ayer Capital Management, LP 230 CALIFORNIA, SUITE 600 SAN FRANCISCO CA 94111 1 0 1 0 0001519942 Ayer Capital Partners, LLC 230 CALIFORNIA STREET SUITE 600 SAN FRANCISCO CA 94111 0 0 1 0 0001519940 ACM Capital Partners, LLC 230 CALIFORNIA STREET SUITE 600 SAN FRANCISCO CA 94111 0 0 1 0 0001413350 Venkatesan Jay 230 CALIFORNIA STREET SUITE 600 SAN FRANCISCO CA 94111 0 0 1 0 Common stock 2013-05-22 4 J 0 5600887 4.9 A 5604015 I See Footnote Warrant 1.00 2013-05-22 4 C 0 1 0 D 2011-07-26 2016-07-26 Common stock 2400000 0 I See Footnote Warrant 1.00 2013-05-22 4 C 0 1 0 D 2012-02-20 2017-02-20 Common stock 960000 0 I See Footnote Convertible Note 1.25 2013-05-22 4 C 0 1 1.25 D 2011-07-26 2012-11-30 Common stock 3000000 0 I See Footnote Corporate Loan 1.25 2013-05-22 4 C 0 1 1.25 D 2012-05-03 2012-06-30 Common Stock 1100000 0 I See Footnote These securities are held by investment funds and a managed account, the investment advisor of which is Ayer Capital Management, LP (the "Advisor"), ACM Capital Partners, LLC ("ACM")is the General Partner of the Advisor, Ayer Capital Partners, LLC (the "GP") is the General Partner of the investment funds. Mr. Venkatesan is the managing member of ACM and the General Partner of the GP. Each of the Advisor, ACM, the GP, and Mr. Venkatesan disclaims beneficial ownership of these securities except to the extent of its or his pecuniary interest thereof, and the filing of this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose. The Issuer completed a restructuring transaction, resulting in a revised capital structure, as reported by the Issuer in its Form 8K filed on May 29, 2013 (the "Restructuring"). As a result of the Restructuring, Ayer Capital exchanged all of its convertible notes and warrants for shares of common stock of the Issuer (the "Exchange Shares"), purchased new shares of common stock pursuant to a Stock Purchase Agreement (the "Investment Shares"), and received certain shares as a result of a re-pricing feature (the "Repricing Shares"). The number of shares currently held by Ayer Capital represents the sum of the shares held prior to the Restructuring, the Exchange Shares, the Investment Shares and Repricing Shares. Lion Biotechnologies, Inc announced a 1-for-100 reverse stock split effective September 26, 2013. The shares and price reflect the post-reverse stock split amounts. On behalf of Ayer Capital Management, LP, Jay Venkatesan, 2014-02-14 On behalf of Ayer Capital Partners, LLC, Jay Venkatesan, General Partner 2014-02-14 On behalf of ACM Capital Partners LLC, Jay Venkatesan, Managing Member 2014-02-14 Jay Venkatesan 2014-02-14